13 July 2022 | Wednesday | News
Image Source : Public Domain
Discovery Life Sciences™ (Discovery), the biospecimens and biomarkers™ specialists, today announced the acquisition of AllCells, a leading provider of clinical-grade (GMP)-compliant primary cellular products and exclusive use research (RUO). With more than 30 cumulative years of experience in cell and gene therapy (CGT), AllCells and Discovery will focus on delivering revolutionary products and services with greater speed and reliability to meet the entire CGT process, from basic discovery to commercialization. ®
Founded in 1998 by Jay Tong, M.D., AllCells is a leading global provider for the acquisition and customization of primary cellular products that support a variety of applications at CGT. The combination of AllCells' proven industry expertise with Discovery's specialization in biospecims and biomarkers establishes the premier provider of essential raw materials and analytical services to accelerate applications at CGT.
"We are very excited to welcome the AllCells team to the Discovery family," said Glenn Bilawsky, CEO of Discovery. "Bringing these two large companies together creates a scalable end-to-end solution that gives our customers unprecedented access to reliable human cellular raw materials with integrated multi-omic analytical services to support cell and gene therapies."
Discovery will combine its existing CGT products and services with AllCells to create a new business unit called AllCells, a Discovery Life Sciences company. Effective immediately, Danny Zheng, Chief Executive Officer and President of AllCells, will lead the combined entity.
The integration of Discovery's growing CGT business with AllCells also creates one of the largest groups of specialty donor clients in the industry. FDA-registered donor collection facilities and GMP-compliant cleanrooms are located adjacent to characterization laboratories. This strategic proximity facilitates immediate processing and cryopreservation, ensuring an unmatched level of quality and offering customers faster and more affordable access to a broader and more engaged donor pool, with characterization for each client's specific programs.
Zheng said, "We built our organization to be an extension of our customer's supply chain. By offering advice on donor programs, high-quality apheresis collections, customization services and GMP-compliant raw materials, our specialized team will continue to offer a high-level, customer-centric approach to ensure our users' needs are met with superior products and services that fit any schedule and scale. Our strategy resembles and reinforces Discovery's 'science at your service' approach and our unified offerings will further accelerate our customers' strategic and vital cell and gene therapy programs."
"The promise of CGT having an impact on patient health is unquestionable, but improvements in manufacturing and reproducibility are needed to expand treatable patient populations and improve treatment paradigms," said Dominic Clarke, CGT technical director at Discovery. "Our solution offers access to the entire process, from RUO to GMP raw materials, and is based on integrated, absolute characterization at scale to support the rapidly expanding needs of the industry."